๐๐ก๐๐ฉ๐ข๐ง๐ ๐ญ๐ก๐ ๐ง๐๐ฑ๐ญ ๐ ๐๐ง๐๐ซ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐
๐๐ ๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐๐ซ๐ฌ.
Today we published our nine-month results for 2026, which show significant operational successes and a clear improvement in revenue and operating income compared to the same period last year.
13
Formycon invites to Conference Call on 2026 Nine-Month Results. To join the earnings call on November 12, please use the following link:
webcast-eqs.com/formycon-202โฆ
83
โWe believe that PK-focused clinical approaches have the potential to reshape biosimilar development in a lasting way,โ says Dr Andreas Seidl, CSO of Formycon:
lnkd.in/ebzuA4vD
1
97
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
formycon.com/en/investor-relโฆ
1
54
Formycon invites to conference call on 2026 half-year results: webcast-eqs.com/formycon-202โฆ
53
In the #NebenwerteWelt podcast, Formycon CFO Enno Spillner shares insights on the basics of #biosimilars and what makes the dynamic biosimilar market so attractive
youtu.be/xWkjpQK9FOI?si=BLJ4โฆ
1
42
Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026
formycon.com/en/blog/press-rโฆ
Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: webcast-eqs.com/formycon-202โฆ
2
178
๐
๐จ๐ซ๐ฆ๐ฒ๐๐จ๐งโ๐ฌ ๐๐๐ฅ๐ข๐๐๐ซ๐๐๐ฉ๐ญ ๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐๐ซ๐ฌ ๐ฅ๐๐ฎ๐ง๐๐ก๐๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐: formycon.com/en/blog/press-rโฆ
For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: formycon.com/en/blog/press-rโฆ
For full details on the financial results, please refer to the Annual Report on our website: formycon.com/wp-content/uploโฆ
1
45
๐๐จ๐ง๐๐๐ซ๐๐ง๐๐ ๐๐๐ฅ๐ฅ
๐จ๐ง ๐ญ๐ก๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐ ๐๐๐๐ ๐
๐ข๐ฌ๐๐๐ฅ ๐๐๐๐ซ
To follow the conference live, please register via the following link: webcast-eqs.com/formycon-202โฆ
Access the replay at: formycon.com/en/investor-relโฆ
28
The European Biotechnology Science & Industry Guide is more than just a โWho's Whoโ of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.
51
๐
๐จ๐ซ๐ฆ๐ฒ๐๐จ๐ง ๐ฌ๐๐๐ฎ๐ซ๐๐ฌ ๐ฅ๐ข๐๐๐ง๐ฌ๐ ๐๐๐ญ๐ ๐๐จ๐ซ ๐
๐๐๐๐๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐ ๐๐ง๐ ๐๐ฎ๐ซ๐ญ๐ก๐๐ซ ๐ญ๐๐ซ๐ซ๐ข๐ญ๐จ๐ซ๐ข๐๐ฌ
Market launches by commercialization partners across Europe to start in May 2026
formycon.com/en/blog/press-rโฆ
71
๐ฌ
Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytrudaยฎ
formycon.com/en/blog/press-rโฆ
We are happy to announce another milestone in our global commercialization journey for FYB206:
formycon.com/en/blog/press-rโฆ
4
159
The FDA has approved Nufymcoยฎ, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formyconโs pioneering position in high-quality biosimilar #development: formycon.com/en/blog/press-rโฆ
2
101
Zydus Lifesciences Limited to commercialize Formyconโs Keytruda biosimilar FYB206 in the US and Canada: formycon.com/en/blog/press-rโฆ
1
116
Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytrudaยฎ biosimilar candidate in the #MENA region: formycon.com/en/blog/press-rโฆ
2
102
Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio
formycon.com/en/blog/press-rโฆ
2
144















